Key result
Sacubitril/valsartan was associated with an incremental cost-effectiveness ratio of SGD 74,592 (USD 55,198) per QALY gained compared to enalapril in patients with heart failure and reduced ejection fraction.
Why the study?
Is sacubitril/valsartan cost-effective compared to enalapril in patients with HFrEF from the Singapore healthcare payer perspective?
Is sacubitril/valsartan cost-effective compared to enalapril in patients with HFrEF from the Singapore healthcare payer perspective?
Answers are grounded in this paper and cite their sources.
At its current daily price, sacubitril/valsartan may not be cost-effective compared to enalapril for HFrEF patients in the Singapore healthcare setting.
BACKGROUND: Sacubitril/valsartan reduces cardiovascular death and hospitalizations for heart failure (HF). However, decision-makers need to determine whether its benefits are worth the additional costs, given the low-cost generic status of traditional standard of care. AIMS: To evaluate the cost-effectiveness of sacubitril/valsartan compared to enalapril in patients with HF and reduced ejection fraction, from the Singapore healthcare payer perspective. METHODS: A Markov model was developed to project clinical and economic outcomes of sacubitril/valsartan vs enalapril for 66-year-old patients with HF over 10 years. Key health states included New York Heart Association classes I-IV and deaths; patients in each state incurred a monthly risk of hospitalization for HF and cardiovascular death. Sacubitril/valsartan benefits were modeled by applying the hazard ratios (HRs) in PARADIGM-HF trial to baseline probabilities. Primary model outcomes were total and incremental costs and quality-adjusted life years (QALYs) and the incremental cost-effectiveness ratio (ICER) for sacubitril/valsartan relative to enalapril Results: Compared to enalapril, sacubitril/valsartan was associated with an ICER of SGD 74,592 (USD 55,198) per QALY gained. A major driver of cost-effectiveness was the cardiovascular mortality benefit of sacubitril/valsartan. The uncertainty of this treatment benefit in the Asian sub-group was tested in sensitivity analyses using a HR of 1 as an upper limit, where the ICERs ranged from SGD 41,019 (USD 30,354) to SGD 1,447,103 (USD 1,070,856) per QALY gained. Probabilistic sensitivity analyses showed the probability of sacubitril/valsartan being cost-effective was below 1%, 12%, and 71% at SGD 20,000, SGD 50,000, and SGD 100,000 per QALY gained, respectively. CONCLUSIONS: At the current daily price sacubitril/valsartan may not represent good value for limited healthcare dollars compared to enalapril in reducing cardiovascular morbidity and mortality in HF in the Singapore healthcare setting. This study highlights the cost-benefit trade-off that healthcare professionals and patients face when considering therapy.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2017) studied Heart failure and reduced ejection fraction (n=1,000). Sacubitril/valsartan vs. Enalapril 10 mg twice daily was evaluated on Incremental cost-effectiveness ratio (ICER) (SGD 74,592 per QALY gained). Sacubitril/valsartan was associated with an incremental cost-effectiveness ratio of SGD 74,592 (USD 55,198) per QALY gained compared to enalapril in patients with heart failure and reduced ejection fraction.
Synapse has enriched 10 related papers. Consider them for comparative context: